New CEO of Priavoid

New CEO of Priavoid

Philipp Bürling appointed CEO of Priavoid Philipp Bürling appointed CEO of Priavoid We are pleased to inform you that Philipp Bürling has been appointed CEO of Priavoid GmbH as of September 1st, 2020. Philipp holds Master degrees in business informatics and business...
Priavoid Headquarters at LSC Düsseldorf

Priavoid Headquarters at LSC Düsseldorf

Priavoid Headquaters at Life Science Center Düsseldorf Priavoid relocated its headquarters to the Life Science Center Düsseldorf, Merowinger Platz 1A, 40225 Düsseldorf, Germany News & Events: Priavoid closes financing round12. Februar 2021 Sprunginnovationsprojekt...
Seed Investment

Seed Investment

Seed InvestmentMarch 28th, 2019 Priavoid obtained seed investment. News & Events: Priavoid closes financing round12. Februar 2021 Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie11. Februar 2021 Alzheimer´s Research: Important Milestone for...
Prof. Willbold´s interview with PharmaVentures

Prof. Willbold´s interview with PharmaVentures

Prof. Willbold´s interview with PharmaVenturesNovember 14th, 2017 Learn more Prof. Dieter Willbold talks with Summer Park of PharmaVentures at Biotech and Money Investival, London in 2017. News & Events: Priavoid closes financing round12. Februar 2021...
Clinical trial with PRI-002

Clinical trial with PRI-002

Clinical trial with PRI-002 Learn More PRI-002 completed the MAD part of the phase I study up to 320mg/subject/day orally for 28 days to healthy volunteers with very good safety results on 03rd April 2019. News & Events: Priavoid closes financing round12. Februar...